# CSAG2

## Overview
CSAG2, or Cancer/Testis Antigen Family 2, is a gene that encodes the protein CSAG family member 2, which is also known as Taxol-resistance-associated gene-3 (TRAG-3). This protein is categorized as a cancer/testis antigen, which is typically expressed in various cancer types and in the testis, but not in normal tissues. CSAG2 has been implicated in the development of resistance to paclitaxel, a chemotherapeutic agent, particularly in ovarian cancer. The protein's expression is regulated by the RNA binding protein CPEB4, which enhances the translation of CSAG2 mRNA, thereby contributing to drug resistance. Due to its role in chemoresistance, CSAG2 is being studied as a potential biomarker for predicting clinical outcomes and as a target for therapeutic intervention in cancer treatment (Materna2007Taxolresistanceassociated; Zhang2021CPEB4-Promoted).

## Structure


## Clinical Significance
CSAG2, also known as the Taxol-resistance-associated gene-3 (TRAG-3), is implicated in the development of paclitaxel resistance in ovarian cancer. Overexpression of CSAG2 is observed in paclitaxel-resistant ovarian cancer cells and is associated with poor clinical outcomes following chemotherapy. Studies have shown that CSAG2 expression is higher in patients who do not respond to chemotherapy compared to those with stable disease or a positive response, suggesting its potential as a predictive marker for clinical outcomes (Materna2007Taxolresistanceassociated).

The role of CSAG2 in drug resistance is further supported by its interaction with CPEB4, an RNA binding protein that enhances the translation of CSAG2 mRNA. CPEB4 overexpression in ovarian cancer cells leads to increased CSAG2 expression, contributing to paclitaxel resistance. Knockdown of CSAG2 has been shown to reduce this resistance, indicating that the CPEB4/CSAG2 axis is crucial for the development of drug resistance in ovarian cancer (Zhang2021CPEB4-Promoted).

Overall, CSAG2's expression levels and its regulation by CPEB4 play significant roles in the resistance to paclitaxel treatment in ovarian cancer, making it a potential target for therapeutic intervention.


## References


[1. (Materna2007Taxolresistanceassociated) Verena Materna, Paweł Surowiak, Irina Kaplenko, Marek Spaczyński, Zhenfeng Duan, Maciej Zabel, Manfred Dietel, and Hermann Lage. Taxol-resistance-associated gene-3 (trag-3/csag2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Archiv, 450(2):187–194, January 2007. URL: http://dx.doi.org/10.1007/s00428-006-0346-7, doi:10.1007/s00428-006-0346-7. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00428-006-0346-7)

[2. (Zhang2021CPEB4-Promoted) Yaqing Zhang, Hongyun Gan, Fei Zhao, Xiaomei Ma, Xiaofeng Xie, Rui Huang, and Jin Zhao. Cpeb4-promoted paclitaxel resistance in ovarian cancer in vitro relies on translational regulation of csag2. Frontiers in Pharmacology, January 2021. URL: http://dx.doi.org/10.3389/fphar.2020.600994, doi:10.3389/fphar.2020.600994. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2020.600994)